[Federal Register: October 1, 2001 (Volume 66, Number 190)]
[Notices]               
[Page 49957-49958]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01oc01-60]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY-51-01]

 
Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 639-7090. Send written 
comments to CDC, Desk Officer, Human Resources and Housing Branch, New 
Executive Office Building, Room 10235, Washington, DC 20503. Written 
comments should be received within 30 days of this notice.
    Proposed Project: Gonococcal Isolate Surveillance Project (GISP) 
(0920-0307)--Revision--The National Center for HIV, STD, and TB 
Prevention (NCHSTP), Centers for Disease Control and Prevention (CDC) 
proposes to continue data collection for the Gonococcal Isolate 
Surveillance Project (OMB No. 0920-0307). This request is a three-year 
extension of clearance.
    The purposes of the Gonococcal Isolate Surveillance Project (GISP) 
are (1) to monitor trends in antimicrobial susceptibility of strains of 
Neisseria gonorrhoeae in the United States and (2) to characterize 
resistant isolates. GISP provides critical surveillance for 
antimicrobial resistance, allowing for informed treatment 
recommendations. GISP was begun in 1986 as a voluntary surveillance 
project and now involves five regional laboratories and 26 publicly 
funded sexually transmitted disease (STD) clinics around the country. 
The STD clinics submit up to 25 gonococcal isolates per month to the 
regional laboratories, which measure susceptibility to a panel of 
antibiotics. Limited demographic and clinical information corresponding 
to the isolates are submitted directly by the clinics to CDC.
    Data gathered through GISP are used to alert the public health 
community to changes in antimicrobial resistance in Neisseria 
gonorrhoeae which may impact treatment choices, and to guide 
recommendations made in CDC's STD Treatment Guidelines, which are 
published periodically.
    Under the GISP protocol, clinics are asked to provide 25 isolates 
per month. However, due to low volume at some sites, clinics submit an 
average of 17 isolates per clinic per month, providing an average of 88 
isolates per laboratory per month. The estimated time for clinic 
personnel to abstract data is 11 minutes per response. Based on 
previous laboratory experience in analyzing gonococcal isolates, we 
estimate 88 gonococcal isolates per laboratory each month. The 
estimated burden for each participating laboratory is one hour per 
response. Annual burden hours for this data collection is 6,300.

[[Page 49958]]



----------------------------------------------------------------------------------------------------------------
                                                                                                  Average burden
               Respondents                    Number of      Number of responses per respondent    per  response
                                             respondents                                             (in hrs.)
----------------------------------------------------------------------------------------------------------------
Clinic Form 1............................              26  204..................................           11/60
                                                           (12 x 17)............................
Laboratory Form 2........................               5  1,056................................           60/60
                                                           (12 x 88)............................
Laboratory Form 3........................               5  48...................................           12/60
                                                           (12 x 4).............................
----------------------------------------------------------------------------------------------------------------


    Dated: September 24, 2001.
Nancy E. Cheal,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control and Prevention.
[FR Doc. 01-24436 Filed 9-28-01; 8:45 am]
BILLING CODE 4163-18-P